141 related articles for article (PubMed ID: 9194208)
1. A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis.
Kim HA; Song YW
Rheumatol Int; 1997; 17(1):5-9. PubMed ID: 9194208
[TBL] [Abstract][Full Text] [Related]
2. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine].
Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H
Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388
[TBL] [Abstract][Full Text] [Related]
3. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].
Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R
Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis.
Nobunaga M; Yasuda M
Agents Actions Suppl; 1993; 44():105-9. PubMed ID: 8372720
[TBL] [Abstract][Full Text] [Related]
5. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study).
Sagawa A; Fujisaku A; Ohnishi K; Mukai M; Yasuda I; Amasaki Y; Shimizu M; Ichikawa K; Ohsaki H
Mod Rheumatol; 2011 Jun; 21(3):251-7. PubMed ID: 21188453
[TBL] [Abstract][Full Text] [Related]
6. Gigantomastia induced by bucillamine.
Sakai Y; Wakamatsu S; Ono K; Kumagai N
Ann Plast Surg; 2002 Aug; 49(2):193-5. PubMed ID: 12187348
[TBL] [Abstract][Full Text] [Related]
7. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. epidemiology of DMARDs treatment in Japan.
Nagashima M; Shu G; Yamamoto K; Yamahatsu S; Yoshino S
Clin Exp Rheumatol; 2005; 23(1):27-35. PubMed ID: 15789884
[TBL] [Abstract][Full Text] [Related]
8. Bucillamine suppresses human Th1 cell development by a hydrogen peroxide-independent mechanism.
Morinobu A; Wang Z; Kumagai S
J Rheumatol; 2000 Apr; 27(4):851-8. PubMed ID: 10782806
[TBL] [Abstract][Full Text] [Related]
9. Low-dose D-penicillamine therapy in rheumatoid arthritis. A controlled, double-blind clinical trial.
Williams HJ; Ward JR; Reading JC; Egger MJ; Grandone JT; Samuelson CO; Furst DE; Sullivan JM; Watson MA; Guttadauria M; Cathcart ES; Kaplan SB; Halla JT; Weinstein A; Plotz PH
Arthritis Rheum; 1983 May; 26(5):581-92. PubMed ID: 6342625
[TBL] [Abstract][Full Text] [Related]
10. [A case of rheumatoid arthritis associated with agranulocytosis during bucillamine treatment].
Negishi M; Yamazaki J; Hosaka M; Iwabuchi H; Matsuda A; Kanemitsu H; Hiramatsu K; Kaga S; Hashimoto M; Kasama T
Ryumachi; 1994 Jun; 34(3):651-5. PubMed ID: 8052932
[TBL] [Abstract][Full Text] [Related]
11. OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study.
Verstraeten A; Sileghem A; Dequeker J
Scand J Rheumatol; 1990; 19(6):422-31. PubMed ID: 2259898
[TBL] [Abstract][Full Text] [Related]
12. Membranous glomerulonephritis in patients with rheumatoid arthritis.
Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T
Clin Ther; 1994; 16(6):1000-6. PubMed ID: 7697679
[TBL] [Abstract][Full Text] [Related]
13. Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases.
Nakagomi D; Ikeda K; Hirotoshi K; Kobayashi Y; Suto A; Nakajima H
Rheumatol Int; 2013 Mar; 33(3):793-7. PubMed ID: 22090009
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis.
Nakajima M; Ueda N; Ohara H; Abe M; Kinoshita M
Mod Rheumatol; 2009; 19(4):384-9. PubMed ID: 19363607
[TBL] [Abstract][Full Text] [Related]
15. Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome.
Hur JW; Lee CW; Yoo DH
J Korean Med Sci; 2006 Jun; 21(3):585-7. PubMed ID: 16778412
[TBL] [Abstract][Full Text] [Related]
16. "Yellow nail syndrome" and rheumatoid arthritis.
Ichikawa Y; Shimizu H; Arimori S
Tokai J Exp Clin Med; 1991 Dec; 16(5-6):203-9. PubMed ID: 1820660
[TBL] [Abstract][Full Text] [Related]
17. [Membranous glomerulonephritis probably related to bucillamine therapy in two patients with rheumatoid arthritis].
Baba N; Nomura T; Sakemi T; Uchida M; Watanabe T
Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):629-34. PubMed ID: 1920943
[TBL] [Abstract][Full Text] [Related]
18. [A case of rheumatoid arthritis complicated with a pneumonitis during concomitant treatment with methotrexate and bucillamine].
Miwa Y; Kaga S; Hanaoka R; Shiozawa F; Hanyuda M; Kasama T; Negishi M; Ide H
Ryumachi; 2002 Feb; 42(1):70-5. PubMed ID: 11925909
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites.
Hashimoto K; Lipsky PE
J Rheumatol; 1993 Jun; 20(6):953-7. PubMed ID: 8350330
[TBL] [Abstract][Full Text] [Related]
20. [A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA].
Minami M; Kaneda K
Ryumachi; 1995 Oct; 35(5):780-91. PubMed ID: 8594657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
